keyword
MENU ▼
Read by QxMD icon Read
search

Measle myeloma

keyword
https://www.readbyqxmd.com/read/28796556/systemic-virotherapy-for-multiple-myeloma
#1
Stefania Oliva, Manuela Gambella, Mario Boccadoro, Sara Bringhen
The multiple myeloma (MM) treatment scenario has changed considerably over the past few years. Several novel targeted therapies are currently under consideration including oncolytic virotherapy. Areas covered: This review provides an analysis of the mechanisms of action of virotherapy, and summarizes the preclinical and clinical studies of systemic virotherapy developed for the treatment of MM. Different types of viruses have been identified, including: adenovirus, vaccinia virus, herpes simplex virus 1, myxoma virus, reovirus, measles virus, vesicular stomatitis virus and coxsackievirus A21...
August 10, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28439108/phase-i-trial-of-systemic-administration-of-edmonston-strain-of-measles-virus-genetically-engineered-to-express-the-sodium-iodide-symporter-in-patients-with-recurrent-or-refractory-multiple-myeloma
#2
A Dispenzieri, C Tong, B LaPlant, M Q Lacy, K Laumann, D Dingli, Y Zhou, M J Federspiel, M A Gertz, S Hayman, F Buadi, M O'Connor, V J Lowe, K-W Peng, S J Russell
MV-NIS is an Edmonston lineage oncolytic measles virus expressing the human sodium iodide symporter-a means for monitoring by non-invasive imaging of radioiodine. Patients with relapsed, refractory myeloma who had explored all other treatment options were eligible for this Phase I trial. Cohort 1 was treated with intravenous MV-NIS, and Cohort 2 received cyclophosphamide 2 days prior to MV-NIS. Thirty-two patients were treated. Cohort 1 initially enrolled to four dose levels without reaching maximum tolerated dose (MTD) and subsequently to two higher dose levels when improved virus manufacture technology made it possible...
April 25, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28228086/clinical-trials-with-oncolytic-measles-virus-current-status-and-future-prospects
#3
Pavlos Msaouel, Mateusz Opyrchal, Angela Dispenzieri, Kah Whye Peng, Mark J Federspiel, Stephen J Russell, Evanthia Galanis
Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives genetically engineered to expressed the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors...
February 22, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/27782084/measles-to-the-rescue-a-review-of-oncolytic-measles-virus
#4
REVIEW
Sarah Aref, Katharine Bailey, Adele Fielding
Oncolytic virotherapeutic agents are likely to become serious contenders in cancer treatment. The vaccine strain of measles virus is an agent with an impressive range of oncolytic activity in pre-clinical trials with increasing evidence of safety and efficacy in early clinical trials. This paramyxovirus vaccine has a proven safety record and is amenable to careful genetic modification in the laboratory. Overexpression of the measles virus (MV) receptor CD46 in many tumour cells may direct the virus to preferentially enter transformed cells and there is increasing awareness of the importance of nectin-4 and signaling lymphocytic activation molecule (SLAM) in oncolysis...
October 22, 2016: Viruses
https://www.readbyqxmd.com/read/26555426/-advances-in-measles-virus-for-cancer-therapy
#5
Duo Zhou, Zheng-yan Zhao
Oncolytic virotherapy is a novel cancer therapy. Vaccine-attenuated strains of measles virus(MV)is an ideal candidate for oncolytic virotherapy which has an excellent safety record. Vaccine-attenuated MV uses CD46 and Nectin-4 molecule as major entry receptors into cells. Vaccine-attenuated MV can selectively infect and kill a wide variety of cancer cells in vitro and in vivo. With the development of molecular cloning, scientists have successfully rescued cDNA of vaccine-attenuated MV and increased its oncolytic efficiency with molecular engineering techniques...
July 2015: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
https://www.readbyqxmd.com/read/25233543/mayo-breakthrough-virus-may-destroy-bone-marrow-cancer
#6
(no author information available yet)
No abstract text is available yet for this article.
September 2014: Mayo Clinic Health Letter
https://www.readbyqxmd.com/read/25157763/measles-vaccine-strains-for-virotherapy-of-non-small-cell-lung-carcinoma
#7
Manish R Patel, Blake A Jacobson, Holly Belgum, Ahmad Raza, Ahad Sadiq, Jeremy Drees, Hengbing Wang, Joseph Jay-Dixon, Ryan Etchison, Mark J Federspiel, Stephen J Russell, Robert A Kratzke
INTRODUCTION: Oncolytic virus therapy is a promising therapy for numerous tumor types. Edmonston-strain measles virus (MV) has been tested in clinical trials for ovarian cancer, glioma, and myeloma. Therefore, the antitumor activity of MV against non-small-cell lung cancer (NSCLC) was assessed. METHODS: Human NSCLC cells and immortalized lung epithelial cell lines, Beas2B, were infected with either MV-producing green fluorescent protein or MV-producing carcinoembryonic antigen...
August 2014: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/24835529/taming-measles-virus-to-create-an-effective-cancer-therapeutic
#8
EDITORIAL
John C Bell
No abstract text is available yet for this article.
July 2014: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/24835528/remission-of-disseminated-cancer-after-systemic-oncolytic-virotherapy
#9
Stephen J Russell, Mark J Federspiel, Kah-Whye Peng, Caili Tong, David Dingli, William G Morice, Val Lowe, Michael K O'Connor, Robert A Kyle, Nelson Leung, Francis K Buadi, S Vincent Rajkumar, Morie A Gertz, Martha Q Lacy, Angela Dispenzieri
MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10(11) TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites...
July 2014: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/24829351/faster-replication-and-higher-expression-levels-of-viral-glycoproteins-give-the-vesicular-stomatitis-virus-measles-virus-hybrid-vsv-fh-a-growth-advantage-over-measles-virus
#10
Camilo Ayala-Breton, Luke O J Russell, Stephen J Russell, Kah-Whye Peng
UNLABELLED: VSV-FH is a hybrid vesicular stomatitis virus (VSV) with a deletion of its G glycoprotein and encoding the measles virus (MV) fusion (F) and hemagglutinin (H) envelope glycoproteins. VSV-FH infects cells expressing MV receptors and is fusogenic and effective against myeloma xenografts in mice. We evaluated the fusogenic activities of MV and VSV-FH in relationship to the density of receptor on the target cell surface and the kinetics of F and H expression in infected cells...
August 2014: Journal of Virology
https://www.readbyqxmd.com/read/23842448/amalgamating-oncolytic-viruses-to-enhance-their-safety-consolidate-their-killing-mechanisms-and-accelerate-their-spread
#11
Camilo Ayala-Breton, Lukkana Suksanpaisan, Emily K Mader, Stephen J Russell, Kah-Whye Peng
Oncolytic viruses are structurally and biologically diverse, spreading through tumors and killing them by various mechanisms and with different kinetics. Here, we created a hybrid vesicular stomatitis/measles virus (VSV/MV) that harnesses the safety of oncolytic MV, the speed of VSV, and the tumor killing mechanisms of both viruses. Oncolytic MV targets CD46 and kills by forcing infected cells to fuse with uninfected neighbors, but propagates slowly. VSV spreads rapidly, directly lysing tumor cells, but is neurotoxic and loses oncolytic potency when neuroattenuated by conventional approaches...
October 2013: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/23403007/enhancing-cytokine-induced-killer-cell-therapy-of-multiple-myeloma
#12
Chunsheng Liu, Lukkana Suksanpaisan, Yun-Wen Chen, Stephen J Russell, Kah-Whye Peng
Cytokine-induced killer (CIK) cells are in clinical testing against various tumor types, including multiple myeloma. In this study, we show that CIK cells have activity against subcutaneous and disseminated models of human myeloma (KAS-6/1), which can be enhanced by infecting the CIK cells with an oncolytic measles virus (MV) or by pretreating the myeloma cells with ionizing radiation (XRT). KAS-6/1 cells were killed by coculture with CIK or MV-infected CIK (CIK/MV) cells, and the addition of an anti-NKG2D antibody inhibited cytolysis by 50%...
June 2013: Experimental Hematology
https://www.readbyqxmd.com/read/22790962/preclinical-efficacy-of-the-oncolytic-measles-virus-expressing-the-sodium-iodide-symporter-in-iodine-non-avid-anaplastic-thyroid-cancer-a-novel-therapeutic-agent-allowing-noninvasive-imaging-and-radioiodine-therapy
#13
H V Reddi, P Madde, S J McDonough, M A Trujillo, J C Morris, R M Myers, K W Peng, S J Russell, B McIver, N L Eberhardt
Anaplastic thyroid cancer is an extremely aggressive disease resistant to radioiodine treatment because of loss of sodium iodide symporter (NIS) expression. To enhance prognosis of this fatal cancer, we validated the preclinical efficacy of measles virus (MV)-NIS, the vaccine strain of the oncolytic MV (MV-Edm), modified to include the NIS gene. Western blotting analysis confirmed that a panel of eight anaplastic thyroid cancer (ATC)-derived cell lines do not express NIS protein, but do express CD46, the MV receptor...
September 2012: Cancer Gene Therapy
https://www.readbyqxmd.com/read/22318450/efficient-transduction-of-healthy-and-malignant-plasma-cells-by-lentiviral-vectors-pseudotyped-with-measles-virus-glycoproteins
#14
COMPARATIVE STUDY
M Schoenhals, C Frecha, A Bruyer, A Caraux, J L Veyrune, M Jourdan, J Moreaux, F-L Cosset, E Verhoeyen, B Klein
A lot of genes deregulated in malignant plasma cells (PCs) involved in multiple myeloma have been reported these last years. The expression of some of these genes is associated with poor survival. A critical step is to elucidate the biological mechanisms triggered by these gene products. Such studies are hampered by the difficulty to obtain malignant PCs and to genetically modify them. Usual lentiviral vectors (LVs) pseudotyped with vesicular stomatitis virus envelope glycoprotein poorly transduced healthy and malignant PCs...
July 2012: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/22312362/oncolytic-virotherapy-for-hematological-malignancies
#15
Swarna Bais, Eric Bartee, Masmudur M Rahman, Grant McFadden, Christopher R Cogle
Hematological malignancies such as leukemias, lymphomas, multiple myeloma (MM), and the myelodysplastic syndromes (MDSs) primarily affect adults and are difficult to treat. For high-risk disease, hematopoietic stem cell transplant (HCT) can be used. However, in the setting of autologous HCT, relapse due to contamination of the autograft with cancer cells remains a major challenge. Ex vivo manipulations of the autograft to purge cancer cells using chemotherapies and toxins have been attempted. Because these past strategies lack specificity for malignant cells and often impair the normal hematopoietic stem and progenitor cells, prior efforts to ex vivo purge autografts have resulted in prolonged cytopenias and graft failure...
2012: Advances in Virology
https://www.readbyqxmd.com/read/22235810/oncolytic-measles-virus-encoding-thyroidal-sodium-iodide-symporter-for-squamous-cell-cancer-of-the-head-and-neck-radiovirotherapy
#16
Hongtao Li, Kah-Whye Peng, Stephen J Russell
Oncolytic measles virus (MV) encoding the human thyroidal sodium iodide symporter (MV-NIS) has proved to be safe after intraperitoneal or intravenous administration in patients with ovarian cancer or multiple myeloma, respectively, but it has not yet been administered through intratumoral injection in humans. Squamous cell carcinoma (SCC) of the head and neck (SCCHN) usually is locally invasive and spreads to the cervical lymph nodes, which are suitable for the intratumoral administration of oncolytic viruses...
March 2012: Human Gene Therapy
https://www.readbyqxmd.com/read/22116376/polyinosinic-acid-decreases-sequestration-and-improves-systemic-therapy-of-measles-virus
#17
Y-P Liu, C Tong, A Dispenzieri, M J Federspiel, S J Russell, K-W Peng
Off-target binding or vector sequestration can significantly limit the efficiency of systemic virotherapy. We report here that systemically administered oncolytic measles virus (MV) was rapidly sequestered by the mononuclear phagocytic system (MPS) of the liver and spleen in measles receptor CD46-positive and CD46-negative mice. Since scavenger receptors on Kupffer cells are responsible for the elimination of blood-borne pathogens, we investigated here if MV uptake was mediated by scavenger receptors on Kupffer cells...
March 2012: Cancer Gene Therapy
https://www.readbyqxmd.com/read/22046569/oncolytic-virotherapy-for-multiple-myeloma-past-present-and-future
#18
Chandini M Thirukkumaran, Don G Morris
Multiple myeloma (MM) is a B-cell malignancy that is currently felt to be incurable. Despite recently approved novel targeted treatments such as lenalidomide and bortezomib, most MM patients' relapse is emphasizing the need for effective and well-tolerated therapies for this deadly disease. The use of oncolytic viruses has garnered significant interest as cancer therapeutics in recent years, and are currently under intense clinical investigation. Both naturally occurring and engineered DNA and RNA viruses have been investigated preclinically as treatment modalities for several solid and hematological malignancies...
2011: Bone Marrow Research
https://www.readbyqxmd.com/read/21508164/comparative-study-of-immune-status-to-infectious-agents-in-elderly-patients-with-multiple-myeloma-waldenstrom-s-macroglobulinemia-and-monoclonal-gammopathy-of-undetermined-significance
#19
Johanna Karlsson, Björn Andréasson, Nahid Kondori, Evelina Erman, Kristian Riesbeck, Harriet Hogevik, Christine Wennerås
Whereas patients with multiple myeloma (MM) have a well-documented susceptibility to infections, this has been less studied in other B-cell disorders, such as Waldenstrom's macroglobulinemia (WM) and monoclonal gammopathy of undetermined significance (MGUS). We investigated the humoral immunity to 24 different pathogens in elderly patients with MM (n = 25), WM (n = 16), and MGUS (n = 18) and in age-matched controls (n = 20). Antibody titers against pneumococci, staphylococcal alpha-toxin, tetanus and diphtheria toxoids, and varicella, mumps, and rubella viruses were most depressed in MM patients, next to lowest in WM and MGUS patients, and highest in the controls...
June 2011: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/21325484/measles-virotherapy-in-a-mouse-model-of-adult-t-cell-leukaemia-lymphoma
#20
Cecilia Parrula, Soledad A Fernandez, Bevin Zimmerman, Michael Lairmore, Stefan Niewiesk
Adult T-cell leukaemia/lymphoma (ATL) is a highly aggressive CD4(+) T-cell malignancy caused by human T-cell leukaemia virus type 1. Measles virus (MV) oncolytic therapy has been reported to be efficient in reducing tumour burden in subcutaneous xenograft models of lymphoproliferative disorders such as myeloma, B-cell lymphoma and cutaneous T-cell lymphoma, but its potential to reduce tumour burden in disseminated lymphoproliferative disorders such as ATL remains to be determined. In this study, MV oncolytic therapy was evaluated in the MET-1/NOD/SCID xenograft mouse model of ATL...
June 2011: Journal of General Virology
keyword
keyword
56032
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"